SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Akero Therapeutics, Inc. 
 CA
  SEC # 1744659


        
    Click to view...      Registrant      About      Filings      Files      Relationships      Names    
  Topics  
    Web       

248  Topics
Topic emoji
 within the 

Show:   Most-Recent Document   All Documents   And:   Exhibits  

 As Of  Filing  Doc.  Page    Title Docs.
  In ascending order
3/6/24424B51About this prospectus
1About this prospectus supplement
4/26/24New Filing!  DEF 14A1Appendix A
1Approval of an Amendment to our Fourth Amended and Restated Certificate of Incorporation
2/29/2410-K1Audited Consolidated Financial Statements
1Business
3/6/24424B51Cautionary note regarding forward looking statements
5/17/23424B51Cautionary Note Regarding Forward-Looking Statements
3/6/24424B51Cautionary statement regarding forward-looking statements
4/26/24New Filing!  DEF 14A1Certain Relationships and Related Party Transactions
2/29/2410-K1Certain Relationships and Related Transactions, and Director Independence
1Changes in and Disagreements with Accountants on Accounting and Financial Disclosure
3/6/24424B51Company, The
4/26/24New Filing!  DEF 14A1Compensation Discussion and Analysis
11/13/2310-Q1Condensed Consolidated Balance Sheets (Unaudited)
1Condensed Consolidated Financial Statements
1Condensed Consolidated Statements of Cash Flows (Unaudited)
1Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)
1Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited)
2/29/2410-K1Consolidated Balance Sheets as of December 31, 2023 and 2022
1Consolidated Statements of Cash Flows for the years ended December 31, 2023, 2022 and 2021
1Consolidated Statements of Operations and Comprehensive Loss for the years ended December 31, 2023, 2022 and 2021
1Consolidated Statements of Stockholders' Equity (Deficit) for the years ended December 31, 2023, 2022 and 2021
1Controls and Procedures
4/26/24New Filing!  DEF 14A1Corporate Governance
2/29/2410-K1Cybersecurity
11/13/2310-Q1Defaults Upon Senior Securities
3/6/24424B51Description of capital stock
1Description of debt securities
1Description of units
1Description of warrants
1Dilution
2/29/2410-K1Directors, Executive Officers and Corporate Governance
1Disclosure Regarding Foreign Jurisdictions that Prevent Inspections
3/6/24424B51Dividend policy
4/28/23DEF 14A1Election of Class I Directors
4/26/24New Filing!  DEF 14A1Election of Class II Directors
2/29/2410-K1Executive Compensation
11/13/2310-Q1Exhibits
2/29/2410-K1Exhibits, Financial Statement Schedules
3/6/24424B51Experts
11/13/2310-Q1Financial Informat Ion
2/29/2410-K1Financial Statements and Supplementary Data
1Form 10-K Summary
4/26/24New Filing!  DEF 14A1General Information
1Householding
3/6/24424B51Incorporation by reference
2/29/2410-K1Item 1
11/13/2310-Q1Item 1A
1Item 2
1Item 3
1Item 4
1Item 5
1Item 6
3/6/24424B51Legal matters
11/13/2310-Q1Legal Proceedings
2/29/2410-K1Management's Discussion and Analysis of Financial Condition and Results of Operations
1Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
5/17/23424B51Material U.S. Federal Income Tax Consequences to Non-U.S. Holders
3/6/24424B51Material U.S. federal income tax considerations to non-U.S. holders
11/13/2310-Q1Mine Safety Disclosures
4/26/24New Filing!  DEF 14A1Non-Binding Advisory Vote on Compensation of our Named Executive Officers
2/29/2410-K1Notes to Consolidated Financial Statements
11/13/2310-Q1Notes to Unaudited Condensed Consolidated Financial Statements
2/29/2410-K1Other Information
4/26/24New Filing!  DEF 14A1Other Matters
2/29/2410-K1Part I
1Part Ii
1Part Iii
1Part Iv
3/6/24424B51Plan of distribution
2/29/24S-81Power of Attorney (included on signature page)
2/29/2410-K1Power of Attorney (included on the signatures pages hereto)
1Principal Accounting Fees and Services
4/26/24New Filing!  DEF 14A1Principal Stockholders
4/28/23DEF 14A1Proposal 1 -- Election of Class I Directors
4/26/24New Filing!  DEF 14A1Proposal 1 -- Election of Class II Directors
1Proposal 2 -- Ratification of the Appointment of Deloitte & Touche LLP as Akero's Independent Registered
1Proposal 3 -- Non-Binding Advisory Vote on Compensation of our Named Executive Officers
1Proposal 4 -- Approval of an Amendment to our Fourth Amended and Restated Certificate of Incorporation
3/6/24424B51Prospectus supplement summary
4/28/23DEF 14A1Proxy Statement for the 2023 Annual Meeting of Stockholders
4/26/24New Filing!  DEF 14A1Proxy Statement for the 2024 Annual Meeting of Stockholders
4/28/23DEF 14A1Public Accounting Firm for the Fiscal Year Ending December 31, 2023
4/26/24New Filing!  DEF 14A1Public Accounting Firm for the Fiscal Year Ending December 31, 2024
2/29/2410-K1Quantitative and Qualitative Disclosures about Market Risk
4/26/24New Filing!  DEF 14A1Ratification of the Appointment of Deloitte & Touche LLP as Akero's Independent Registered
2/29/2410-K1Report of Independent Registered Accounting Firm
4/26/24New Filing!  DEF 14A1Report of the Audit Committee
2/29/2410-K1Reserved
3/6/24424B51Risk factors
1Securities we may offer
2/29/2410-K1Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
11/13/2310-Q1Signatures
4/26/24New Filing!  DEF 14A1Stockholder Proposals
3/6/24424B51Table of Contents
1The company
1Underwriting
11/13/2310-Q1Unregistered Sales of Equity Securities and Use of Proceeds
2/29/2410-K1Unresolved Staff Comments
3/6/24424B51Use of proceeds
1Where you can find more information

Top

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Mon., Apr. 29, 10:48:43.2am ET